MONT-TREMBLANT, Quebec--(BUSINESS WIRE)--FibroGen, Inc. (FibroGen) announced today the presentation of the full data set from a clinical study of patients with idiopathic pulmonary fibrosis (IPF) treated for 48 weeks with the investigational drug FG-3019. In the study, lung fibrosis, as measured by quantitative high resolution computed tomography (HRCT), was reduced in a substantial portion of patients who received FG-3019. FG-3019 is a monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), a central mediator of fibrotic disease. The data are being presented in oral and poster presentations at the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF).
Help employers find you! Check out all the jobs and post your resume.
